Skip to main content
Contact Us
Back to Homepage
follow us on linkedin
follow us on facebook
follow us on twitter
follow us on youtube
Investors & Media
News
Events & Presentations
Financials
Quarterly Results
Annual Reports
SEC Filings
Interactive Financials
Form 8937
Stock Information
Stock Details
Analyst Coverage
Governance
Governance Documents
Committee Composition
Resources
Investor FAQs
Investor Email Alerts
ZTALMY Factsheet
Site Search
toggle main menu
News
Investors & Media
News
Events & Presentations
Financials
Quarterly Results
Annual Reports
SEC Filings
Interactive Financials
Form 8937
Stock Information
Stock Details
Analyst Coverage
Governance
Governance Documents
Committee Composition
Resources
Investor FAQs
Investor Email Alerts
ZTALMY Factsheet
Normal
Press release year list
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
12/13/2019
Marinus Pharmaceuticals Announces Closing of $70 Million Public Offering of Common Stock and Concurrent Private Placement Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
12/13/2019
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
12/12/2019
Marinus Pharmaceuticals Appoints Elan Ezickson to Board of Directors
12/11/2019
Marinus Pharmaceuticals Announces Pricing of $65 Million Public Offering of Common Stock and Concurrent Private Placement
12/11/2019
Corrected Press Release: Marinus Pharmaceuticals Announces Pricing of $65 Million Public Offering of Common Stock and Concurrent Private Placement
12/10/2019
Marinus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Concurrent Private Placement
12/09/2019
Marinus Announces Ganaxolone Orphan Epilepsy Program Updates Including Planned Clinical Program in Tuberous Sclerosis Complex
12/07/2019
Marinus Presents Additional Data from Ganaxolone Phase 2 Trial in Refractory Status Epilepticus at the American Epilepsy Society Annual Meeting
11/27/2019
Marinus Pharmaceuticals Announces Presentations on Ganaxolone at AES Annual Meeting
11/08/2019
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/06/2019
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter Financial Results
10/29/2019
Marinus Pharmaceuticals Appoints Joe Hulihan, M.D., as Chief Medical Officer
10/17/2019
Marinus Phase 2 Clinical Data on Ganaxolone in RSE Presented at Neurocritical Care Society Meeting
09/27/2019
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
09/26/2019
Marinus Pharmaceuticals Announces Positive Top-Line Results With Ganaxolone in Phase 2 Refractory Status Epilepticus Trial
08/23/2019
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
08/08/2019
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter Financial Results
07/23/2019
Marinus Pharmaceuticals Announces Data from Magnolia and Amaryllis Phase 2 Studies in Women with Postpartum Depression
06/19/2019
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
06/03/2019
Marinus Pharmaceuticals to Participate at Upcoming Investor Conferences
05/01/2019
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2019 Financial Results
03/11/2019
Marinus Pharmaceuticals Provides Business Update and 2018 Financial Results
03/06/2019
Marinus Pharmaceuticals Initiates Phase 3 Study in Children with PCDH19-Related Epilepsy
03/05/2019
Marinus Pharmaceuticals to Present at the Cowen Healthcare Conference
02/26/2019
Marinus Announces Leadership Transition
02/20/2019
Marinus Pharmaceuticals to Present at the Leerink Healthcare Conference
02/05/2019
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/25/2019
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)